Nectar Lifesciences Ltd
NECLIFE
Company Profile
Business description
Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.
Contact
SCO 38-39, Sector 9-D
B-1011/1012, 10th Floor NAURANG HOUSE
Chandigarh160009
INDT: +91 1725047915
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
1,686
Stocks News & Analysis
stocks
Better times ahead for these cheap ASX shares?
Our analysts think the outlook looks fairly good for these two undervalued and unloved ASX dividend payers.
video
ASX dividend stocks for 2025
With dividend yields at 25-year lows, it's time to rethink ASX stocks for income according to James Gruber.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,699.10 | 57.60 | -0.66% |
| CAC 40 | 8,206.56 | 17.43 | 0.21% |
| DAX 40 | 22,844.50 | 46.41 | 0.20% |
| Dow JONES (US) | 44,556.34 | 10.26 | 0.02% |
| FTSE 100 | 8,766.73 | 1.28 | -0.01% |
| HKSE | 22,898.45 | 78.36 | -0.34% |
| NASDAQ | 20,041.26 | 14.49 | 0.07% |
| Nikkei 225 | 39,164.61 | 105.79 | -0.27% |
| NZX 50 Index | 13,033.36 | 17.76 | -0.14% |
| S&P 500 | 6,129.58 | 14.95 | 0.24% |
| S&P/ASX 200 | 8,419.20 | 61.80 | -0.73% |
| SSE Composite Index | 3,351.54 | 27.05 | 0.81% |